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Abstract
Head and neck squamous cell carcinoma (HNSCC) is characterized by aggressive behavior with a 
propensity for metastasis and recurrence. Here we report a comprehensive analysis of the 
molecular and clinical features of HNSCC that govern patient survival. We find that TP53 
mutation is frequently accompanied by loss of chromosome 3p, and that the combination of both 
events associates with a surprising decrease in survival rates (1.9 years versus >5 years for TP53 
mutation alone). The TP53-3p interaction is specific to chromosome 3p, rather than a consequence 
of global genome instability, and validates in HNSCC and pan-cancer cohorts. In Human 
Papilloma Virus positive (HPV+) tumors, in which HPV inactivates TP53, 3p deletion is also 
common and associates with poor outcomes. The TP53-3p event is modified by mir-548k 
expression which decreases survival even further, while it is mutually exclusive with mutations to 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondence to Trey Ideker (tideker@ucsd.edu).. 
CONTRIBUTIONS
A.M.G., R.K.O., and T.I. conceived the study. A.M.G carried out most analyses. R.K.O., J.P.S., M.C., C.S.C, E.E.C., S.M.L, Q.T.N., 
and D.N.H. provided expertise. M.H. and H.C. aided in bioinformatic analysis. A.M.E. and J.G. collected and compiled clinical 
follow-up data for UPMC cohort. A.M.G. and T.I. wrote the manuscript with assistance from other authors.
The authors declare no competing financial interests.
URLS
Study source code and analysis notebook repository, https://github.com/theandygross/TCGA Broad Firehose, https://




Nat Genet. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:













RAS signaling. Together, the identified markers underscore the molecular heterogeneity of 
HNSCC and enable a new multi-tiered classification of this disease.
INTRODUCTION
It is increasingly appreciated that the diversity of clinical outcomes in HNSCC is likely a 
reflection of the molecular heterogeneity of the tumor population1,2,3. Previous studies have 
led to the identification of a variety of genes and other molecular features for stratifying 
HNSCC tumors, such as efforts to cluster gene expression profiles to define subtypes4,5,6,7,8. 
To comprehensively define this heterogeneity of common tumor types including HNSCC, 
The Cancer Genome Atlas (TCGA) project has generated multi-tiered molecular profiles for 
over 7000 patient tumors, providing an unprecedented opportunity to study the complex 
interrelations among fundamentally different types of molecular events and clinical 
outcomes such as patient survival.
Here we have built on the infrastructure established by TCGA to systematically and 
transparently unravel these complex relationships for HNSCC. To this effect, we obtained 
all available molecular and clinical data from TCGA (unpublished, TCGA HNSCC working 
group) as of the January 15, 2014 Firehose run and have documented all data-processing and 
analysis in a series of IPython Notebooks9 (Methods, Supplementary Table 1). Five tiers 
of data – somatic mutations, chromosomal aberrations, mRNA expression, microRNA 
expression, and clinical variables – were analyzed for a total of 378 HNSCC patients 
resulting in measurements of over 34,000 molecular or clinical values for each patient 
(Supplementary Fig. 1a). Because old age and HPV status are associated with distinct 
molecular profiles and clinical outcomes1 (Supplementary Fig. 2), we focused analysis on 
the 250 patients under 85 years of age with HPV– tumors and complete molecular profiles.
RESULTS
Identification of prognostic events in HNSCC
We first sought to distill this multi-tiered, genome-wide dataset into a set of informative 
molecular and clinical events with potential relevance to cancer. First, individual somatic 
mutations and mRNA expression levels were integrated with knowledge of human 
molecular pathways to define aggregate ‘pathway-level events’ (Supplementary Fig. 1b-e, 
Methods). Second, both individual and pathway events were filtered to select those that 
occur at high frequency (somatic mutations, chromosomal aberrations) or differential 
expression (mRNA and microRNA levels) in tumor versus normal tissue. The result of this 
analysis was a pool of 878 total events combined over all five tiers of data (Supplementary 
Fig. 1a).
Next, we screened for individual events within each data type that are strongly predictive of 
survival, identifying 82 prognostic events out of the 878 (Fig. 1a, Supplementary Table 2). 
Among somatic mutation events, TP53 mutation was most strongly predictive overall, 
resulting in poor prognosis (Hazard Ratio 2.9 ±0.8, Benjamini Hochberg corrected P < 
0.01). As has been observed previously, survival outcomes were dependent on the TP53 
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protein domain affected by the mutation or its predicted functional status10 (Fig. 1b). 
However, we found that patients with mutations predicted as non-disruptive of function 
nonetheless had worse prognosis than patients with wild-type TP53 (Hazard Ratio 2.2±0.7, 
P = 0.03). Among copy-number alterations, the most significant survival association was 
with heterozygous chromosomal deletions on the 3p arm which also led to very poor 
prognosis (Fig. 1a, Hazard Ratio 3.5±1.1, Benjamini Hochberg corrected P = 0.002). 
Further analysis of chromosome 3p revealed that many patients have a deletion spanning a 
large fraction of the arm with increasing frequency of deletion approaching a fragile site in 
the 3p14.2 region11 (Supplementary Fig. 3). Although general chromosomal instability 
(CIN) as well as deletion of many individual chromosomal regions have previously been 
implicated as diagnostic1,12 and prognostic7,13,14,15 markers, we find that the 3p event in 
particular was responsible for the majority of the impact on survival when compared with 
global rates of gene deletion (Fig. 1c).
TP53 and 3p events co-occur and their combination predicts worse clinical outcome
It has previously been shown that genetic alterations often act by redundant or synergistic 
mechanisms to confer a growth advantage in the tumor16,17. Under the hypothesis that 
individual events might act in concert, we next examined the 82 prognostic events for 
pairwise association across the patient cohort. This analysis identified 33 pairs of events that 
were significantly cooccurring or mutually exclusive (Supplementary Table 3). Among 
these, a particularly striking finding was that mutation of TP53 and deletion of 3p occur very 
frequently together, in 179 of 250 HPV– tumors (Table 1, Fig. 1d). While mutation of TP53 
has previously been associated with chromosomal instability1, we found that TP53 mutation 
associates with 3p loss far more frequently than it does with deletions in other chromosomal 
regions (Supplementary Fig. 4, Supplementary Tables 4-6). Moreover, the combination 
of TP53 and 3p events led to significantly worse survival than was predicted by either event 
independently or additively. Thus the synergistic interaction between TP53 and 3p, with 
respect to both co-occurrence and survival, supports a clear molecular stratification of 
HNSCC tumors with and without this combination of events (Fig. 1c-e, Methods, 
Supplementary Fig. 5, Supplementary Table 7).
We found that the TP53-3p combination of events is associated with advanced tumor stage, 
although the stratification remains prognostic at all stages (Supplementary Figure 6). 
Furthermore, the prognostic effect cannot be explained by clinical covariates alone and is 
particularly strong for smokers under 75 years old (175 patients, the majority of the TCGA 
cohort) for which the hazard ratio was 5.1 for the TP53-3p event relative to patients without 
this combination (Supplementary Fig. 7, Methods).
To explore whether the interaction between TP53 mutation and 3p deletion could be 
replicated in new patients, we obtained 126 additional HNSCC HPV– samples that had been 
deposited in TCGA while our initial study was underway (not included in the January 15, 
2014 Firehose run). While these new patients did not yet have sufficient clinical follow-up 
for survival analysis, we indeed observed the same high co-occurrence of TP53 mutation 
and 3p deletion (Table 1).
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We also analyzed clinical follow-up data for 48 HNSCC HPV– tumors from the University 
of Pittsburgh Medical Center3 for which the exome sequencing and copy number profiles 
had been previously collected after surgery (UPMC cohort, Supplementary Table 1). We 
observed that in this cohort, patients whose tumors contain the TP53-3p aggregate event 
have substantially worse prognosis than patients with TP53 mutation alone, confirming the 
very large effect seen in the TCGA population (Fig. 2a and Table 1). TP53 and 3p events 
also co-occurred in the UPMC cohort, although with a lower effect size than in the two 
TCGA cohorts (Table 1); we suspect this is due to the much higher error rate of DNA 
sequencing in the earlier UPMC study, resulting in false-negative mutation calls (Methods).
We also sought evidence for the TP53-3p combination in patients with HPV+ tumors, in 
which TP53 is inactivated via interaction with HPV viral proteins18,19. Analysis of 59 HPV+ 
tumors from the TCGA and UPMC cohorts showed that TP53 mutation is very rare in the 
presence of HPV (Odds Ratio 0.01, P = 10−27 by Fisher's Exact Test), consistent with the 
expectation that the mutation confers little selective advantage once TP53 is inactivated by 
HPV. Among HPV+ tumors, the 25 tumors with 3p deletion had significantly worse 
prognosis than the 34 without the 3p event (Hazard Ratio 5.5 ± 2.6, P = 0.004). This finding 
lends further support for interaction between TP53 and chromosome 3p with respect to 
survival and stratifies the growing population of patients with HPV+ tumors19 (Fig. 2b).
Another question was whether the TP53-3p interaction is specific to HNSCC or has broader 
support across diverse tissues. For this purpose, we performed a pan-cancer analysis based 
on all publicly available molecular data in TCGA (excluding HNSCC patients), covering 
4404 patients over an additional 17 cancer types20 (Methods). Although these tissues are 
molecularly heterogeneous and present with different patient outcomes (Supplementary 
Fig. 8a-c), we nonetheless found compelling evidence for both the co-occurrence and 
impact on survival of TP53 mutation and 3p deletion in this broader cohort, even when 
tissue type, patient age, and staging are accounted for (Fig. 2c-d, Table 1).
Characterization of subtypes defined by combined TP53-3p event
Finally, we investigated whether the major subtypes defined by TP53 and 3p status (Fig. 1e) 
could be subdivided further by additional molecular markers (Methods). Indeed, we found 
that the 179 patients with the combined TP53-3p event were well stratified by the additional 
presence of microRNA mir-548k (Fig. 3a, Supplementary Fig. 7c) or mutation of the 
MUC5B gene (Fig. 3b, Supplementary Fig. 7d), both of which were associated with worse 
prognosis. Mir-548k is near CCND1 and FADD on 11q13.3, which is commonly amplified 
in HNSCC14. Very recently, this micro-RNA has been shown to have oncogenic behavior in 
Oesophegeal Squamous Cell Carcinoma cell lines21. While we found that 11q13.3 
amplification is associated with survival to a lesser degree than mir-548k expression, the 
prognostic effect seems to be specific to the expression of the micro-RNA (Fig. 3c, 
Supplementary Fig. 9).
Among patients lacking the TP53-3p event combination, we found strong enrichment for 
mutations to Caspase 8 as well as Ras and components of Ras signaling (Table 2, 
Supplementary Fig. 1b). These enrichments were replicated in the TCGA molecular 
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validation cohort (Table 2). The mutual exclusivity of Caspase 8 or Ras with TP53-3p 
provides further support for a TP53-3p defined subtype, and it implicates alternative routes 
to tumor progression in the absence of the TP53-3p event.
DISCUSSION
As we approach a full inventory of driver events in cancer22, a key next step is to map and 
decode the complex network of interactions among individual events. Here, such an analysis 
was performed to identify a definitive stratification of head and neck cancer based on the 
largest tissue bank and dataset in existence. We have shown that TP53 mutation, a well-
studied driver event which leads to poor patient survival, is nearly always accompanied by 
specific loss of chromosome 3p (Fig. 1d, Table 1). As has been argued for other cancer 
mutations17,23, the frequent co-occurrence of TP53 and 3p alteration implies a selective 
advantage of cells acquiring both genomic events. In this study, the detection of the TP53-3p 
interaction was possible due to the high prevalence of each event individually, and their high 
(marginal) associations with patient survival.
While our study focused almost entirely on a single compelling interaction, our full analysis 
uncovered an additional 32 interactions in HNSCC which remain to be investigated 
(Supplementary Table 3). It is likely that this number is an underestimate, as low 
frequency and/or non-prognostic events were not evaluated. As cancer cohorts become 
larger, analyses such as this will become more powered, creating the opportunity to re-
evaluate the cancer landscape from the perspective of pairwise and ultimately higher-order 
interactions among events.
Our analysis identifies two distinct clinical and molecular paths to cancer in HPV– HNSCC 
patients. The first group, characterized by TP53 mutation and loss of the 3p chromosome, is 
associated with advanced clinical stage and common risk factors such as smoking. 
Nonetheless, this group tends to have very poor outcomes even when evaluated 
independently of these risk factors (Supplementary Fig. 7). The second group of patients, 
lacking the TP53-3p combination of events, is characterized by mutations to RAS signaling 
and Caspase 8 (Table 2) and, ultimately, less aggressive tumors.
Further study is clearly warranted to elucidate the molecular underpinnings of these two 
groups of patients, with the goal of using such molecular stratification alongside clinical 
variables to inform patient treatment. Open questions relate to mechanism and the ordering 
of TP53 and 3p events. What is the factor or factors encoded on chromosome 3p that are 
responsible for the interaction with TP53? Does one event necessarily precede the other and 
is a particular order required for poor survival? It is plausible that genomic instability 
primed by TP53 mutation gives rise to loss of activity of a key factor encoded on 
chromosome 3p, but other scenarios are possible. Regardless, since the interaction of 3p 
with TP53 or HPV status is independent of tumor stage, treatment of HNSCC patients might 
be modified to coincide with this specific molecular classification. In HPV– HNSCC, the 
need for patient-tailored treatment programs is especially great, as we are currently in an era 
where we have maximized toxicity of existing regimens without necessarily improving 
outcome in cancers.
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Our results also underscore the importance and value of public efforts such as TCGA in 
gathering, organizing, and distributing genomic data. Our work builds on the exemplary 
TCGA data collection and analysis pipeline20 to integrate data across different measurement 
platforms, with the goal of finding higher-order interactions of molecular events. Following 
the example of TCGA, we have documented and made public all analyses conducted in this 
study, ranging from data download to processing, exploratory analyses, statistical modeling, 
and visualization (Methods). With such a large and complex dataset, transparency and 
reproducibility of analysis is essential to provide a clear understanding of the methodology 
and to allow for further mining of results and extension to new datasets.
ONLINE METHODS
1. Availability
All data-retrieval and processing steps are documented in a series of IPython notebooks9 
available along with source code online at (https://github.com/theandygross/TCGA). These 
notebooks provide fully executable instructions for reproduction of the analyses and 
generation of figures and statistics for this study.
2. Molecular Data
Data were obtained from The Cancer Genome Atlas Genome Data Analysis Center (GDAC) 
Firehose website (https://confluence.broadinstitute.org/display/GDAC/) using the 
firehose_get data-retrieval utility. All data were downloaded from the January 15th, 2014 
standard data and analyses run unless otherwise specified. In order to maintain coherency of 
the analysis across different data layers and cancer types, we used Level 3 normalized 
molecular data as the input to our analysis. The use of the GDAC pipeline is intended to 
make these results easy to update as more TCGA data become available.
For a number of pan-cancer samples we generated mutation calls from TCGA aligned BAM 
files obtained from the UCSC Cancer Genomics Hub (https://cghub.ucsc.edu/). These calls 
were only used for patients with sequenced exome data that have yet go through the 
Firehose processing pipeline. Somatic mutation calls were made by running the MuTect 
mutation calling program24 and the Genome Analysis Toolkit (GATK) 
SomaticIndelDetector25 function on targeted regions with default parameters. All steps for 
downloading and processing this data are documented in the analysis notebooks and 
accompanying software repository. All mutation calls generated for this analysis are 
included as Supplementary Table 8. While these calls have yet to go through manual 
curation, we benchmarked this pipeline against TCGA working group mutation calls and 
found very high overlap with 94% sensitivity and 96% specificity.
3. Pathway Data
Pathway data were downloaded from the Molecular Signatures Database26 (mSigDB). 
Version 3 of the canonical pathway gene-sets was used for this analysis.
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4. Candidate biomarker construction
Mutation calls were extracted from the annotated MAF files obtained from the Firehose and 
filtered to include only non-silent mutations. Each patient was associated with a binary 
vector in which each position represents a gene; the position is set to 1 if the gene is 
observed to harbor one or more mutations in the patient and set to 0 otherwise. Mutation 
meta-markers were constructed by collapsing genes within a pathway gene-set via a logical 
OR such that the pathway is considered altered in a patient if any of its genes have a 
mutation (Supplementary Fig. 1b-c). Pathway markers that were characterized by a single 
highly mutated gene or were highly correlated with mutation rate (Mann-Whitney U test, P 
< .01) were filtered.
Copy-number aberrations were extracted from the GISTIC227 processing pipeline included 
in the standard Firehose analysis run. For biomarker construction data aggregated on 
significantly altered lesions (as deemed significant at the default 99% confidence settings) 
were used.
mRNA and miRNA expression data were obtained from the Level 3 normalized gene-by-
patient matrices generated as part of the Firehose analysis pipeline. Data were log2 
transformed. Genes/ miRNAs were first filtered based on differential expression comparing 
the full set of tumor expression profiles with the 34 profiles available for matched normal 
tissue (t-test, cutoff at P < .01). A pattern of background expression was estimated by taking 
the first principal component of non-differentially expressed genes or miRNAs. This 
background signal is meant to approximate the most common non-tumor related variation in 
expression due to inherent properties of the cohort such as population substructure or tissue 
specific expression changes. Real valued features with high correlation (Pearson 
Correlation, P < 10−5) to this background expression pattern were filtered. For the survival 
analysis, only the top 300 (of a possible 20502) differentially expressed genes were included 
in the analysis to limit the burden of multiple hypothesis correction (all 251 differentially 
expressed miRNA were used).
Markers used in this analysis consisted of binary markers and continuous valued markers. 
Binary markers were used when expression was only present (having more than ½ read per 
million) in a moderate fraction of the cohort (between 20 patients and half of the cohort). 
Real valued gene and miRNA expression levels were used for differentially expressed 
features not assigned as binary markers. Gene expression meta-markers were constructed 
from the loading of the first principal component of the reduced gene-by-patient matrix 
defined by each gene set. Due to similarity of gene-sets causing redundant gene expression 
meta-markers, marker pairs with high correlation (Spearman rho > .7) were reduced to a 
single informative marker by choosing the marker with the greatest differential expression. 
For the survival analysis, continuous valued markers were transformed into binary events 
prior to testing by setting a threshold that minimized the difference in variance between the 
resulting two groups. This was used to capture the skew of the distribution and assign the 
patients on the tail of the expression distribution as having an expression event 
(Supplementary Fig. 1e).
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Clinical data were downloaded directly from the TCGA Data Portal (https://tcga-
data.nci.nih.gov/tcga/). All outcomes reported relate to all-cause survival. Survival times 
were censored after five years to reduce the confounding effect of patient age. For Fig. 2d, 
survival times were censored after three years to show the specific effect within this time 
window, but all other figures and all statistics cited in the paper use five-year survival. 
While data on comorbidity is limited for this cohort, from other studies we can estimate the 
competing mortality within this time-frame to be about 20%28,29. We expect the actual 
effect of such confounding to be minimal as separation in the survival curves that we 
observe generally occurs within the first two years, during which time we expect non-cancer 
associated death rates to be much lower.
For the primary and secondary survival screens, clinical data with missing data were used 
but statistics were only calculated on patients with data reported. In multivariate analysis 
(Supplementary Figure 7) missing value indicators were used.
6. HPV Status
HPV calls from sequencing data were obtained from the TCGA HNSCC analysis working 
group. Due to the incompleteness of this dataset, this information was supplemented with 
HPV status called from a PCR-based MassArray Assay diagnostic provided on the TCGA 
data portal for patients where sequence-based data were not available.
7. Prioritization of Prognostic Events
Feature selection is preformed prior to prognostic event prioritization. Events are selected 
for which at least 5% of patients are assigned to each group.
Prognostic events (Fig. 1a) are prioritized via a likelihood ratio test comparing a Cox-
proportional hazards model30 fit with a candidate biomarker and covariates against a null 
model fit with the covariates alone. Age and the binary variable patient age > 75 are used as 
covariates (both age variables are used to model a non-linear association of patient age with 
survival). A multiple-hypothesis testing correction is employed which uses the method of 
Benjamini and Hochberg31 to control for the false discovery rate across the entire pooled 
space of tested features. After multivariate testing, a univariate log-rank test is assessed for 
each event and features with high multivariate significance, but low univariate significance 
(P < 0.05) are filtered from the pool of prognostic events.
As discussed in the text and in Figure 3, we conducted a second prognostic screen within 
the 179 patients with the TP53-3p aggregate event. For this analysis feature construction 
was repeated, resulting in 1008 candidate biomarkers (note that this number was higher than 
the primary screen due to more events passing the 5% threshold). During this secondary 
screen, we found the patient year of diagnosis to have a large impact on outcomes. For this 
reason we included this variable as a covariate in this screen.
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8. Statistical Analysis of TP53-3p Interaction on Survival
To asses the role of an interaction term in a statistical model of patient outcomes we 
performed leave-one-out cross-validation on a logistic regression model as shown in 
Supplementary Figure 5. To convert the survival data into a binary classification problem, 
we organized patients into two classes depending on whether they were surviving or 
deceased at T years after surgery. In this analysis, the ratio of deceased to surviving patients 
is artificially high due to the ability to observe a death in a shorter followup than the full 
time interval required to annotate a patient as surviving (i.e. the basis of the Cox censorship 
problem). To reduce this bias, we removed patients with an observed death but a time of 
surgery after a set year (2013 – (T – 1)). As the problem was often unbalanced (the number 
of surviving patients differed from the number of deceased), re-weighting was preformed to 
give both classes equal weight. A multivariate Cox model fit to the most significant model is 
also shown in Supplementary Table 7.
9. University of Pittsburg Medical Center Cohort
3p chromosomal status was estimated via the median copy number of the twelve genes on 
the 3p14.2 locus. Matched exome and copy-number data were available for 48 / 63 patients 
with HPV– tumors. In preliminary analysis we found the UPMC cohort to have a 
significantly lower overall mutation rate than the TCGA cohort, with a median of 73 
mutations per patient as compared to 104 mutations per patient in TCGA (Mann-Whitney U 
test, P < .001). This can likely be attributed lower depth of coverage and/or less 
sophisticated variant calling techniques as the UPMC study was one of the first large whole 
exome molecular cohorts and predates the TCGA data collection by about two years.
10. Pan-cancer Analysis
Pan-cancer data were downloaded and processed in the same manner as the HNSCC cohort. 
3p chromosomal status was estimated via the median copy number of the twelve genes on 
the 3p14.2 locus.
In order to limit the heterogeneity of the pan-cancer cohort such that differences in 
molecular characteristics could be assessed, we performed a number of pre-processing steps. 
This reduced the patient cohort from 7081 to 4404 patients appropriate for survival analysis 
through the following filters:
Only primary tumors were used for all patients, metastatic tumors were discarded. 
Glioblastoma patients were excluded due to the extremely low survival rate (6% 
five year survival).
Diffuse large b-cell lymphoma, kidney chromophobe, thyroid carcinoma, and 
prostate adenocarcinoma patients were removed due to extremely high rates of 
survival in the cohorts (84%, 86%, 90%, and 96% five year survival).
Adrenocortical carcinoma, esophageal carcinoma, and pancreatic adenocarcinoma 
were excluded due to low sample counts (14, 39, and 69 patients in each tissue, 
respectively). Patients older than 85 years of age were excluded from the analysis 
to limit confounding from age (115 patients, Hazard ratio = 2.2 ± 3).
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Patients with high levels of residual tumor were excluded (66 patients, Hazard ratio 
= 2.9 ± .5).
Stage IV patients were excluded (612 patients, Hazard ratio = 2.0 +/- .1)
To limit circularity, HNSCC patients were excluded from all pan-cancer 
calculations but remain Supplementary Fig. 8 to allow for comparison to other 
tissue types.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Prognostic effects and co-occurrence of TP53 and 3p
a, Five-year survival (error bars indicate 95% CI) for the most significant events of each 
category (colors). Numbers above bars represent number of patients with each event. b, 
Comparison of 5-year survival for patients with different types of non-silent TP53 mutations 
verses wild-type patients. L2 and L3 represent TP53 binding domains. Numbers in 
parentheses represent number of patients with a given mutation, patients with multiple TP53 
mutations are represented multiple times in this plot. P-value represents log-rank test for 
TP53 mutation types excluding wild type. c, Hazard ratios for multivariate Cox model fit 
with 3p deletion and global deletion rate (CIN) across different patient sets (age covariate 
not shown, error bars indicate 95% CI, p-values represent significance of likelihood ratio 
test for model fit with and without 3p deletion). d, Venn diagram showing co-occurrence of 
TP53 mutation and deletions on the 3p chromosome. e, Kaplan-Meyer curves showing 
survival outcome for all combinations of 3p deletion and TP53 mutation events (colors 
correspond to patient subsets in panel d).
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Figure 2. Replication of TP53-3p association
a, Survival comparison of patients with TP53-3p aggregate event versus those with only 
TP53 mutation in the independent UPMC cohort. b, Loss of 3p chromosomal arm is 
associated with lower survival in patients with HPV+ tumors (TCGA and independent 
cohorts). c, Assessment of 3p loss and TP53 mutation association in TCGA Pan-Cancer 
cohort (HNSCC excluded). d, Corresponding hazard ratio for multivariate model of three-
year truncated survival (shown by dotted line in panel c) when controlling for tissue type, 
age, and stage covariates. Error bars indicate 95% confidence.
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Figure 3. Characterization of molecular subtypes defined by the TP53-3p aggregate event
Patients with the TP53-3p aggregate event can be further stratified by the presence of a, 
mir-548k or b, MUC5B. c, Frequency of high gain amplification (top panel) and association 
with patient survival for gene / miRNA expression (bottom panel) along the 11q13 
chromosomal segment. P-values in a and b are Benjamini-Hochberg-corrected for 1008 
events a secondary prognostic biomarker screen (Methods). All survival associations are 
calculated by a likelihood ratio test with age and year of diagnosis used as covariates in the 
set of 179 patients with the TP53-3p event (TP53-3p negative curves shown for comparison, 
but not used in computation).
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Table 1
Co-occurrence and survival interaction of TP53 and 3p events.
Co-occurrence of TP53 / 3p events Survival Interaction TP53-3p versus TP53




TCGA Discovery 250 6.6 10–4
* 5.6 0.001
Recent TCGA Validation 126 10 10–6 ND ND
UPMC Validation 48 2.5 0.2 6.3 0.01
Pan Cancer Validation 4404 2.0 10–25 1.4 0.002
*
Bonferroni corrected for test space
**
Univariate model in patients under 75 years of age only
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Table 2
Co-occurrence of TP53-3p aggregate event and gene mutations.
Co-occurrence of TP53-3p event and CASP8 
mutation




Cohort n # patients mutated Odds Ratio p # patients mutated Odds Ratio p




    TP53-3p positive 179 6 6
    TP53-3p negative 71 15 17
Recent TCGA Validation 126 20 0.038 7 × 10–8 21 0.86 5 × 10–6
    TP53-3p positive 81 2 4
    TP53-3p negative 45 18 17
†
Biocarta SOS1 Mediated RAS Signaling Pathway (Reacome 524)
*
Bonferroni corrected for test space of 121 gene and pathway mutation events
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